SPGL008
Sponsors
Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions
Advanced Malignant TumorsNMIBC
Phase 1
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
RecruitingNCT07038005
Start: 2025-07-30End: 2027-06-08Target: 96Updated: 2026-02-09
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
Not yet recruitingNCT07445308
Start: 2026-03-12End: 2029-12-21Target: 120Updated: 2026-03-03